ASF 1057

Drug Profile

ASF 1057

Alternative Names: ASF-1057; Monooctanoin/nicotinamide cream

Latest Information Update: 08 Mar 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Astion Pharma A/S
  • Class Nonsteroidal anti-inflammatories; Skin disorder therapies; Small molecules
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Seborrhoeic dermatitis

Most Recent Events

  • 06 Aug 2015 Phase-III development is ongoing in European Union and Canada (EudraCT2006-005637-37, EudraCT2007-004627-38, EudraCT2007-004649-14 )
  • 21 Dec 2010 ASF 1057 is available for licensing as of 21 Dec 2010.
  • 20 Dec 2010 ASF 1057 is still in phase III development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top